NMTC — Neuroone Medical Technologies Income Statement
0.000.00%
Last trade - 00:00- $39.35m
- $34.05m
- $12.10m
- 31
- 25
- 47
- 25
Annual income statement for Neuroone Medical Technologies, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.243 | 2.12 | 3.45 | 3.45 | 12.1 |
| Cost of Revenue | |||||
| Gross Profit | -0.033 | 1.88 | 1.95 | 1.08 | 8.14 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.5 | 12.2 | 15.4 | 15.3 | 16.3 |
| Operating Profit | -10.2 | -10 | -12 | -11.9 | -4.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.95 | -10 | -11.9 | -12.3 | -3.61 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.95 | -10 | -11.9 | -12.3 | -3.61 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.95 | -10 | -11.9 | -12.3 | -3.61 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.95 | -10 | -11.9 | -12.3 | -3.61 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.93 | -0.625 | -0.654 | -0.46 | -0.09 |